AUSTIN, Texas, Aug. 31, 2012 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that the Company has been recognized in the large business category with a Technology Award by the Austin Chamber of Commerce. This year the Austin business community submitted 386 nominations for the Business Awards – the highest number of submissions ever. Of those submissions, 100 finalists were narrowed down to 5 large companies in the Technology category. The Technology Award recognizes a company who has developed an innovative product representing a new and creative solution to addressing a significant problem within their industry.
"We recognize these businesses as paragons for their industries who propel the economy as well as being role models for diverse businesses thriving in Austin," said Austin Chamber Chairman of the Board, Clark Heidrick. "The Greater Austin Business Awards highlight the Austin Chamber's underlying principle of celebrating businesses of all sizes for their achievements and the role they play in the community."
"At Luminex, our passion for innovation inspires us to develop products that improve patient care and laboratory efficiency, reduce overall healthcare costs and accelerate the pace of medical and life-science research," said Patrick J. Balthrop, president and CEO of Luminex Corporation. "All of my colleagues and I are proud of the fact that our products and technology are helping to advance healthcare and science around the world. We are honored to receive the Technology Award for our innovation and technology."Luminex currently employs hundreds of people worldwide and is transforming global healthcare and life-science research through the development, manufacturing, and marketing of proprietary instruments and bioassays for clinical diagnostics and research. A recognized leader in the Austin biotechnology community and the industry, Luminex technology is commercially available worldwide and in use in leading clinical laboratories, as well as major pharmaceutical diagnostic, biotechnology, and life-science companies. Although The company's latest innovation, the xTAG® Gastrointestinal Pathogen Panel (GPP) is not yet cleared for use in the USA, it is transforming the way gastrointestinal infections are diagnosed and has made a significant impact on the industry. Globally 2 billion people become sick and 1.8 million die from gastrointestinal infections each year. xTAG GPP is the first technology of its kind to simultaneously detect bacterial, viral, and parasitic agents responsible for over 95% of gastrointestinal infections in under 5 hours. To date xTAG GPP has been successfully used to manage global epidemics including the malaria epidemic in Papua New Guinea, and the cholera outbreak in Port-au-Prince Haiti. Last year xTAG GPP was used as a front-line screen to triage patients in the deadly German E. coli outbreak and this year was used by University Hospital of Wales as part of Britain's Health Protection Agency Syndromic Surveillance system for the 2012 Olympic Games. This important assay has set a new standard in GI diagnostic patient care and continues to have significant impact in managing global epidemics and saving lives. The 2012 Greater Austin Business Awards finalists and winners were honored at the 12th annual gala event on Thursday evening at the Hilton Austin downtown.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts